NewTimeSpaceWire:Wind data shows that on January 30, Hong Kong stock market innovation drug-related targets collectively weakened, with CSPC Pharmaceutical Group plunging over 12%, while WuXi AppTec and BeiGene fell over 3%. As of 15:00, CSOP Hang Seng Biotech ETF (03174.HK) was down 2.53%.

CSOP Hang Seng Biotech ETF (03174.HK) is issued by CSOP Asset Management Limited and listed on the Hong Kong Stock Exchange, tracking the Hang Seng Biotechnology Index. This is an index fund focused on Hong Kong-listed biotechnology leaders, characterized by high volatility and high elasticity, suitable for investors bullish on innovation drugs, CXO, vaccines, gene therapy and other sectors.

Data shows that in 2025, the total value of Chinese innovative drug BD overseas licensing transactions reached $135.655 billion, with 157 total transactions. Entering 2026, innovative drug overseas licensing continues, with numerous pharmaceutical companies announcing innovative drug outbound deals in January alone.

Domestically, the 2025 National Reimbursement Drug List negotiations showed significant "polarization"—a small number of breakthrough innovative drugs maintained stable prices, while homogeneous products facing intense competition saw larger price cuts. Meanwhile, the centralized renewal procurement for batches 1-8 of national volume-based purchasing requires re-concentrated contract renewals, with inquiry-based price reductions being more moderate than competitive bidding methods.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.